Evidence map›Paper›PMID 42035454›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration.

Lisa Grech, Michelle Allan, David Skvarc, Ruby Hamer, Emily Friedel, Victor Chong, Andrew Giles, Jayashri Kulkarni, Jennifer Neil, Deepa Rajendran and 6 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lisa GrechSchool of Psychology, Deakin University, Burwood, VIC, Australia; Department of Medicine, Monash Health, Monash University, Clayton, VIC, Australia.ORCID 0000-0003-0914-8573
Michelle AllanDepartment of Medicine, Monash Health, Monash University, Clayton, VIC, Australia; Frankston Neurology, Frankston, VIC, Australia.
David SkvarcSchool of Psychology, Deakin University, Burwood, VIC, Australia.ORCID 0000-0002-3334-4980
Ruby HamerSchool of Psychology, Deakin University, Burwood, VIC, Australia; Department of Psychological Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.ORCID 0000-0003-2531-7955
Emily FriedelSchool of Psychology, Deakin University, Burwood, VIC, Australia.
Victor ChongDepartment of Medicine, Monash Health, Monash University, Clayton, VIC, Australia.
Andrew GilesNeurological Alliance Australia, Multiple Sclerosis Australia, North Sydney, NSW, Australia.
Jayashri KulkarniDepartment of Psychiatry, Monash Alfred Psychiatry Research Centre, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-3875-5623
Jennifer NeilMonash School of Medicine, Monash University, Melbourne, VIC, Australia.ORCID 0000-0003-1049-0456
Deepa RajendranDepartment of Medicine, Monash Health, Monash University, Clayton, VIC, Australia; Department of Neurology, Monash Medical Centre, Monash Health, Clayton, VIC, Australia.
Nevin JohnDepartment of Medicine, Monash Health, Monash University, Clayton, VIC, Australia; Department of Neurology, Monash Medical Centre, Monash Health, Clayton, VIC, Australia.ORCID 0000-0002-9834-4498
Martin ShortDepartment of Neurology, Monash Medical Centre, Monash Health, Clayton, VIC, Australia.
Sally ShawPsychology, Livology, Blackburn, VIC, Australia.
Nigel CaswellPeople with MS Victoria, Melbourne, VIC, Australia.
Vanessa FanningPeople with MS Victoria, Melbourne, VIC, Australia.
Ernest ButlerDepartment of Medicine, Monash Health, Monash University, Clayton, VIC, Australia; Frankston Neurology, Frankston, VIC, Australia; Department of Neurology, Peninsula Health, Frankston, VIC, Australia.ORCID 0000-0003-0551-5671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepression is prevalent among individuals with multiple sclerosis (MS) yet frequently goes undetected and untreated. Time constraints are a barrier to depression screening in MS clinics. We evaluated the clinical utility, diagnostic accuracy and feasibility of the Two-Question Screening tool (2QS) for routine, in-clinic depression screening.

objectivesA prospective cross-sectional study of 207 consecutively recruited adults with MS (M

resultsThe 2QS had 100% (95% CI: 71%-100%) sensitivity and 68% (95% CI: 60%-76%) specificity for detecting MDD. Clinician screening adherence was 76%. For the in-clinic subsample, clinician-administered 2QS correlations were SCID-5 MDD,

conclusionsClinician-administered 2QS is valid and feasible for routine depression screening at MS clinic appointments. With high sensitivity and acceptable specificity, the clinician-administered 2QS is suitable to improve depression detection in people with MS.

Indexed as

DepressionMajor Depressive DisorderMass ScreeningMultiple SclerosisPsychiatric Status Rating ScalesAdultCross-Sectional StudiesFeasibility StudiesFemaleHumansMaleMiddle AgedProspective StudiesReproducibility of ResultsSensitivity and SpecificitySurveys and Questionnaires2QSdepressionmultiple sclerosissensitivityspecificityTwo-Question Screening toolValidity

Identifiers

PMID42035454
PMCPMC13646438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.